Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
Ovid Therapeutics Inc. (NASDAQ: OVID) announced its participation in a fireside chat during the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023, at 4:00 p.m. ET. Investors can access a live webcast of the event via the company’s website, with an archived replay available afterward. Ovid focuses on developing medicines for epilepsies and brain disorders, with notable programs including OV329, aimed at treatment-resistant seizures, and OV350, intended for potential epilepsy treatment. The company also has significant interest in soticlestat, currently in Phase 3 trials targeting Dravet and Lennox-Gastaut syndromes.
- None.
- None.
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a fireside chat at the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023 at 4:00 p.m. ET.
A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid’s pipeline of small molecule and genetic medicines candidates seek to meaningfully improve the lives of people and families affected by epilepsies. Ovid is developing OV329, a GABA-aminotransferase inhibitor that is in early clinical development for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation: the potential development and use of OV329, OV350 and the status of Takeda’s two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expected,” “intends,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, the risk that Ovid may not be able to realize the intended benefits of its technology. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 8, 2022, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Contacts
Investors and Media:
Ovid Therapeutics Inc.
Meg Alexander
917-943-6681
malexander@ovidrx.com
OR
Investors:
Argot Partners
Maeve Conneighton
212-596-7231
ovid@argotpartners.com
FAQ
What event will Ovid Therapeutics participate in on March 15, 2023?
What time is Ovid Therapeutics' fireside chat scheduled for?
How can I access the live webcast of Ovid Therapeutics' presentation?
What are the main products being developed by Ovid Therapeutics?
What is the status of soticlestat in Ovid Therapeutics' pipeline?
